STATROL by Alcon is clinical pharmacology the anti-infective components in statrol ophthalmic ointment provide action against specific organisms susceptible to them. Approved for the topical treatment of infections of the external eye, its adnexa caused by susceptible bacteria. First approved in 1974.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
STATROL is a topical ophthalmic antibiotic ointment containing polymyxin B sulfate and neomycin sulfate for treating external eye infections. It provides broad-spectrum coverage against gram-negative and gram-positive bacteria including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. The dual-component mechanism targets susceptible organisms while offering convenient topical administration.
Product approaching loss of exclusivity with moderate competitive pressure (30%) signals defensive positioning and potential organizational restructuring of the brand team.
CLINICAL PHARMACOLOGY The anti-infective components in STATROL Ophthalmic Ointment provide action against specific organisms susceptible to them. Polymyxin B Sulfate and Neomycin Sulfate are active in vitro against Staphylococcus aureus, Escherichia coli, Klebsiella/Enterobacter species, Neisseria…
Worked on STATROL at Alcon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on STATROL offers limited career growth potential given its approaching loss of exclusivity, zero linked job openings, and mature market position. Roles available are primarily defensive and maintenance-focused, suited for professionals seeking stability in a niche therapeutic area rather than advancement.